



Joint Meeting of Coronary Revascularization 07th to 08th December 2018

A Potential Rapid and Sensitive LC-MS/MS Application for Quantification of Amlodipine Besylate Plasma Concentrations in Patients with Hypertension

DOMINIC GERUKA
RESEARCH OFFICER (CHEMIST)
CLINICAL RESEARCH CENTER, SARAWAK GENERAL HOSPITAL



AMLODIPINE BESYLATE (AML)

- ❖ Long-acting 1,4-dihydropyridine calcium channel blocker
- ❖ Acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels




Figure 1: Chemical structure of Amlodipine Besylate (AML)

BURDEN OF HYPERTENSIVE DISEASE

NHMS 2015 HIGHLIGHTS

CARDIOVASCULAR DISEASES

DIABETES MELLITUS

- 17.5% (3.5 million) of adults 18 years and above have diabetes
- 8.3% are known diabetes
- 9.2% are previously undiagnosed with diabetes

HYPERTENSION

- 30.3% (6.1 million) of adults 18 years and above have hypertension
- 13.1% are known to have hypertension
- 17.2% are previously undiagnosed with hypertension

HYPERCHOLESTEROLEMIA

- 47.7% (9.6 million) of adults 18 years and above have hypercholesterolemia
- 9.1% are known to have hypercholesterolemia
- 38.6% are previously undiagnosed with hypercholesterolemia



CLINICAL PRACTICE GUIDELINES

MOH/P/PAK/391.18(GU)

CLINICAL PRACTICE GUIDELINES

Management of Hypertension

5TH EDITION (2018)



Table 5-A. Effective Anti-Hypertensive Combinations Used in Outcome Trials

Effective combination	Patients studied
ACEI + thiazide-like diuretics ⁷⁹	Post stroke
ARB + thiazide ^{82,112}	Hypertensive with Left Ventricular Hypertrophy. High risk hypertensives
CCB + ACEIs or β -blocker + thiazide ⁸⁰	Patients with Coronary Artery Disease
CCB + thiazide ⁸²	High risk hypertensives
CCB + ACEI ¹¹⁰	Medium risk hypertensives with no overt vascular diseases
ACEI + thiazide-like diuretics ⁸³	High risk hypertensives with diabetes
ACEI + CCB ⁸⁴	High risk hypertensives
thiazide-like diuretics + ACEI ¹¹³	Very elderly (>80 years old)
CCB + thiazide or thiazide-like diuretics ¹¹⁴	Medium risk hypertensives
CCB + ARB ¹¹⁴	Medium risk hypertensives
CCB + β - blocker ¹¹⁴	Medium risk hypertensives



Malaysian Society of Hypertension



Ministry of Health Malaysia



Academy of Medicine of Malaysia



CLINICAL UTILITY

- ❖ 83.3% of the patients were prescribed on maximum dose of AML
- ❖ However, blood pressure control is still not satisfactory.
- ❖ Options:
 - Add other antihypertensive drugs
 - Assess patients compliance + decide to add antihypertensive drugs

High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

Maciej Tomaszewski,^{1,2} Christobelle V. Ravi Damani,¹ Joanne Henworth,³ Nil Webster Madir

Conclusions Non-adherence to blood pressure lowering therapy is common, particularly in patients with suboptimal blood pressure control and those referred for

Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence

Pankaj Gupta, Prashanth Patel, Branislav Štrauch, Florence Y. Lai, Artur Akbarov, Gaurav S. Gulsin, Alison Beech, Věra Marešová, Peter S. Topham, Adrian Stanley, Herbert Thurston, Paul R. Smith, Robert Horne, Jiří Widimský, Bernard Keavney, Anthony Heagerty, Nilesh J. Samani, Bryan Williams, Maciej Tomaszewski

ABSTRACT

Objectives Non-adherence is a major cause of suboptimal blood pressure control. Practical tools exist to identify non-adherers. We used a simple urine analysis to determine the prevalence of antihypertensive drug use and its impact on blood pressure.

Abstract—We hypothesized that screening using high-performance liquid chromatography-tandem mass spectrometry–based biochemical analysis could identify nonadherent hypertensive patients. A retrospective analysis was conducted in 2 European countries (United Kingdom and Italy). Patients who were initially diagnosed using biochemical analysis

improvement in adherence and a clinically meaningful BP drop. We further show that a majority of initially nonadherent patients can successfully improve their adherence through repeated LC-MS/MS–based analysis and achieve BP targets similar to those who have been persistently adherent to treatment.



LCMS/MS - Plasma Drug Level Quantification




Figure 3: UHPLC Triple Quad LCMS System

OBJECTIVE

- ❖ To develop & validate an analytical method
- ❖ For rapid and sensitive determination of AML in human plasma, using LC-MS/MS for clinical application



METHODOLOGY (1)

Optimisation:

- ❖ Analytical standard AML (HPLC assay 99.9%)
- ❖ Carbamazepine (HPLC assay 99.0%) as internal standard (IS) at 5ng/mL.



Figure 4: Internal standard & reference standard

METHODOLOGY (2)

- ❖ Column: Poroshell 120EC-C18, 2.1 x 50mm i.d., 2.7 μ m particle size
- ❖ Agilent 1290 Infinity Binary Liquid Chromatography System couple with a mass spectrometer (Agilent 6490 Triple Quadrupole LC/MS system)
- ❖ Assisted by:
 - 0.1% formic acid in ultrapure water
 - Pure acetonitrile
- ❖ Mobile phase: Isocratic elution
- ❖ Flow rate: 0.25mL/min



Figure 5: LC MS/MS column

METHODOLOGY (3)

Mass spectrometry conditions:

- ❖ MRM, positive ion mode
- ❖ Mass transition:

AML m/z 409.1 → 294.0, 409.1 → 238.0


Carbamazepine m/z 237.0 → 194.1, 237.0 → 179.0

- ❖ Sample preparation: Protein precipitation with acetonitrile
- ❖ Retention time: (0.965 min) ~1 minutes AML
- ❖ Total run time: ~3.5 minutes

METHOD VALIDATION (1)

❖ Concentration range, 0.5-500.0 ng/mL

amlodipine - 7 Levels, 7 Levels Used, 7 Points, 7 Points Used, 0 QCs



METHOD VALIDATION (2)

		Amlodipine			
Nominal Concentration (ng/mL)	Day	Intra-Day		Inter-Day	
		% RE	%CV	% RE	%CV
LLOQ (0.5)	1	-0.836	5.47	-2.92	5.74
	2	-3.48	4.41		
	3	-4.45	7.22		
LQC (3)	1	2.53	6.81	-0.771	8.56
	2	-2.21	10.9		
	3	-2.63	8.16		
MQC (200)	1	-0.820	1.20	-6.93	5.53
	2	-10.0	2.15		
	3	-9.90	4.67		
HQC (400)	1	0.520	4.19	-1.49	5.54
	2	1.88	3.31		
	3	-6.87	4.69		
ULOQ (500)	1	5.77	2.06	-2.87	6.06
	2	-3.64	3.56		
	3	-10.7	3.34		



AFTER METHOD SUCCESSFULLY
DEVELOPED AND VALIDATED

**6 Hypertensive patients
prescribed on AML therapy**

READY FOR PLASMA QUANTITATION



RESULT (1) – Baseline Characteristics

Characteristic(s)		Mean (Std. Dev.) / Percentage
Age		51.80 (9.87)
Gender	Male	50%
	Female	50%
Race	Chinese	50%
	Malay	33.3%
	Iban	16.7%
Risk Factor	Dyslipidemia	100%
	Diabetes	66.7%




RESULT (2) – Blood Pressure & Plasma Concentration

Characteristic(s)		Mean (Std. Dev.)
Blood Pressure	SYSTOLIC	142.5 (12.3)
	DIASTOLIC	82.5 (14.7)
AML Plasma Concentration		14.92 ng/mL (8.70)
Range: 6.72 to 29.11 ng/mL		



RESULT (3) – Inverse Relationship



CONCLUSION (1)



CONCLUSION (2)

An inverse relationship was observed between plasma concentrations of AML and BP control.





THANK YOU

